Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms
Neuropsychopharmacology Reports · 2024
DOI: 10.1002/npr2.12490 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neuropsychopharmacology Reports, 2024. Verfasst von Yoshiteru Takekita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan. Hauptthemen laut MEDLINE: Schizophrenia, Transdermal Patch, Antipsychotic Agents, Piperidines. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sumitomo Pharma Co., Ltd.
Abstract (Originalsprache)
Aim
To explore the optimal dose of blonanserin transdermal patch (BNS‐P) based on baseline psychiatric symptomatic characteristics during acute schizophrenia.
Methods
A post hoc cluster analysis was conducted using data from a 6‐week randomized, double‐blind, placebo‐controlled study of BNS‐P (40 or 80 mg/day) in acute schizophrenia. We classified patients into three clusters based on baseline psychiatric symptoms. Efficacy was assessed using the change from baseline to week 6 in the PANSS total score. Safety was assessed by the incidence of adverse events.
Results
Among 577 patients, three clusters were identified, characterized by severe psychiatric (Cluster‐S; n = 122), predominant negative (Cluster‐N; n = 191), and predominant positive (Cluster‐P; n = 264) symptoms. In Cluster‐P, both BNS‐P 40 and 80 mg/day reduced PANSS total score significantly more than placebo ( p = 0.036, effect size = 0.342; p < 0.001, effect size = 0.687, respectively). In Cluster‐S and ‐N, only BNS‐P 80 mg/day reduced PANSS total score significantly more than placebo ( p = 0.045, effect size = 0.497; p = 0.034, effect size = 0.393, respectively). The effect size was greater at 80 mg/day than at 40 mg/day across all clusters. The most common treatment‐emergent adverse events were akathisia and skin‐related adverse events in all clusters.
Conclusion
BNS‐P exhibited a dose‐dependent antipsychotic effect in all clusters, particularly highlighting its efficacy in patients with predominant positive symptoms, even at lower doses. These findings provide novel and valuable insights for determining BNS‐P dose tailoring to individual symptomatic characteristics in real‐world practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan.
- Medical Science, Sumitomo Pharma Co., Ltd, Osaka, Japan.
- Data Science, Sumitomo Pharma Co., Ltd, Tokyo, Japan.
ORCID-Profile: Yoshiteru Takekita, Masaki Kato
Förderung
- Sumitomo Pharma Co., Ltd
Zitieren
APA
Takekita, Y., Matsumoto, Y., Masuda, T., Yoshida, K., Koshikawa, Y., & Kato, M. (2024). Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12490
Vancouver
Takekita Y, Matsumoto Y, Masuda T, Yoshida K, Koshikawa Y, Kato M. Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms. Neuropsychopharmacology Reports. 2024. doi:10.1002/npr2.12490
BibTeX
@article{Takekita2024,
author = {Takekita, Yoshiteru and Matsumoto, Yuji and Masuda, Takahiro and Yoshida, Kazumasa and Koshikawa, Yosuke and Kato, Masaki},
title = {Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms},
journal = {Neuropsychopharmacology Reports},
year = {2024},
doi = {10.1002/npr2.12490}
}
EUVIMED